Teva says its keeping “the long-term stability of the company at the forefront” by agreeing to pay $85m to settle claims brought by the US state of Oklahoma over the company’s alleged “role in fueling the state’s opioid epidemic” through its marketing practises for both generic analgesics and fentanyl brands such as Actiq and Fentora.
Stressing that the settlement did not establish any wrongdoing and that “Teva has not contributed to the abuse of opioids in Oklahoma in any way”, the Israeli group said it was “pleased to put the Oklahoma case behind it and remains prepared to vigorously defend claims against the company,